The “A, B and C” of Her-2 DNA vaccine development

Introduction The development of Her-2 DNA vaccine has progressed through three phases that can be categorized as phase “A”: the pursuit of Her-2 as a tumor-associated “antigen”, phase “B”: tilting the “balance” between tumor immunity and autoimmunity and phase “C”: the on-going “clinical trials”. Ma...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2008-11, Vol.57 (11), p.1711-1717
Hauptverfasser:	Wei, Wei-Zen, Jacob, Jennifer, Radkevich-Brown, Olga, Whittington, Paula, Kong, Yi-chi M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens Cancer Research Cancer vaccines Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Clinical trials Clinical Trials as Topic Humans Immunology Kinases Lymphocytes Medicine Medicine & Public Health Neoplasms - immunology Neoplasms - therapy Oncology Peptides Proteins Receptor, ErbB-2 - genetics Symposium Paper T-Lymphocytes, Regulatory - immunology Transgenic animals Tumors Vaccines, DNA - immunology Vaccines, DNA - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!